Picture of biOasis Technologies logo

BTI biOasis Technologies Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-17.46%
3m-28.89%
6m-33.02%
1yr-49.64%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-53.23%
50d MA-10.22%
200d MA-32.5%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin-1992.43%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
28th Feb 202328th Feb 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of biOasis Technologies EPS forecast chart

Profile Summary

Bioasis Technologies Inc. is a Canada-based development stage biopharmaceutical company engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The Company is engaged in the development of the xB3 platform, a technology for the delivery of therapeutics across the blood brain barrier (BBB) and the treatment of central nervous system (CNS) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. xB3 is based on a human transport protein found circulating at low levels in the blood. The xB3 platform has an efficacy in its ability to shuttle molecules across the blood-brain barrier and reach its targets within the brain through a process called receptor-mediated transcytosis. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Directors

Last Annual
February 28th, 2022
Last Interim
August 31st, 2022
Incorporated
November 3rd, 2006
Public Since
July 24th, 2007
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
79,414,015

BTI Share Price Performance

Upcoming Events for BTI

Similar to BTI

Picture of Advanced Proteome Therapeutics logo

Advanced Proteome Therapeutics

ca flag iconTSX Venture Exchange

Picture of Alpha Cognition logo

Alpha Cognition

ca flag iconTSX Venture Exchange

Picture of Arch Biopartners logo

Arch Biopartners

ca flag iconTSX Venture Exchange

Picture of Ceapro logo

Ceapro

ca flag iconTSX Venture Exchange

Picture of Claritas Pharmaceuticals logo

Claritas Pharmaceuticals

ca flag iconTSX Venture Exchange

FAQ

Or unlock with your email

Or unlock with your email